Alnylam, Medtronic highlight RNAi drug-device combo data

Alnylam Pharmaceuticals ($ALNY) and Medtronic ($MDT), with the support of the nonprofit CHDI Foundation, are evaluating their RNAi drug-device combination to treat Huntington's disease. They point to promising preclinical results suggesting that their test led to "significant silencing" of the huntingtin gene in the striatum and surrounding brain tissue. Details are published in the journal Experimental Neurology. Report

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.